SLC17A7 and central nervous system cancer: Functional analysis showed that overexpression of SLC17A7 in GBM cells reduced proliferation, migration and invasion potential of GBM cells, suggesting SLC17A7 is a potential target for glioma therapy and warrants further investigation.